TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06067594

Intervention type: DIAGNOSTIC_TEST
Intervention: Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement
Description: Fine needle aspiration (FNA) nodule biopsy: FNA is performed on each patient as long as ATA guideline criteria is met. In case of suspicion of medullary carcinoma, in search of a nodule or medullary focus, FNA will be performed on all non-cystic or spongiform nodules larger than 0.8 cm.

Intervention type: DIAGNOSTIC_TEST
Intervention: Fine Needle Aspiration Cytology (FNAC) procedure+calcitonin measurement
Description: Fine needle aspiration (FNA) nodule biopsy: FNA is performed on each patient as long as ATA guideline criteria is met. In case of suspicion of medullary carcinoma, in search of a nodule or medullary focus, FNA will be performed on all non-cystic or spongiform nodules larger than 0.8 cm.
Study: NCT01399359

Intervention type: BEHAVIORAL
Intervention: Counseling session

Intervention type: BEHAVIORAL
Intervention: Counseling session

Intervention type: OTHER
Intervention: Questionnaire 1
Description: Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.

Intervention type: OTHER
Intervention: Questionnaire 1
Description: Questionnaire 1 assesses the recall and understanding of risk information given during the counseling session.

Intervention type: OTHER
Intervention: Questionnaire 2
Description: Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.

Intervention type: OTHER
Intervention: Questionnaire 2
Description: Questionnaire 2 focuses on what factors, other thana the numerical risk-benefit analysis of SERM intake, are important in the decision-making process of women at increased risk for breast cancer.

Intervention type: OTHER
Intervention: online questionnaire
Study: NCT03152786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propranolol Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT03176953

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: prolonged exposure
Description: psychotherapy

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prolonged exposure
Description: psychotherapy
Study: NCT01455116

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Mild Induced Hypothermia
Description: Induction of hypothermia to a target temperature of 32 - 34 degrees Celsius (90 - 93 degrees Fahrenheit
Study: NCT03101709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: patients will receive a standard pre-conditioning regime with cyclophosphamide 0.8-1.0g/m2/day IV for 2 days(Day-5 to day-4).
Study: NCT03176953

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: non-active medication
Study: NCT03101709

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine 25 mg/m2/day IV for 3 days (Day-5 to day-3).

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CART-19
Description: CART-19 cells will be administered using a split dose on day0(10%), 1(30%), and 2(60%) after completion of the chemotherapy.
Study: NCT03795922

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L
Description: MT10109L will be injected into the GL.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo will be injected into the GL.
Study: NCT01611571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: weekly risedronate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Risedronate
Description: weekly risedronate

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: daily teriparatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: daily teriparatide
Study: NCT02208934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999
Description: 5, 10, 20 and 40 mg of PBF-999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999
Description: 5, 10, 20 and 40 mg of PBF-999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999
Description: 5, 10, 20 and 40 mg of PBF-999

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PBF-999
Description: 5, 10, 20 and 40 mg of PBF-999

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo for all dosis of PBF-999
Study: NCT02198209

Intervention type: DRUG
Group type: OTHER
Intervention: Liraglutide
Description: 1. acute study: one injection of 0.6 mg s.c. before IVGTT~2. chronic study: 6 weeks of daily liraglutide administration (1 week at 0.6 mg, 1 week at 1.2 mg, 4 weeks at 1.8 mg, s.c).
Study: NCT02217397

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: OA, CPAP, combination therapy
Study: NCT01615822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 100mg
Description: OZ439 100mg oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 100mg
Description: OZ439 100mg oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 400mg
Description: OZ439 400mg oral suspension, single dose
Study: NCT01611571

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Teriparatide
Description: daily placebo of teriparatide

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo Risedronate
Description: weekly placebo of Risedronic Acid
Study: NCT00548860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric Carboxymaltose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard Medical Care (SMC)
Study: NCT03413878

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing in the simulated avalanche snow
Description: Breathing in the simulated wet or dry avalanche snow with a small or large air pocket

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing in the simulated avalanche snow
Description: Breathing in the simulated wet or dry avalanche snow with a small or large air pocket

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing in the simulated avalanche snow
Description: Breathing in the simulated wet or dry avalanche snow with a small or large air pocket

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing in the simulated avalanche snow
Description: Breathing in the simulated wet or dry avalanche snow with a small or large air pocket
Study: NCT00751088

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tension free vaginal ttape
Description: Patient placed in lithotomic position. 15 mm vaginal incision below urethral meatus. Dissection of the paraurethral space on each side of the incision and of the bladder from the inferior edge of the pubis. Transversal 10 mm skin incisions at level of superior pubic margin. Top-down or bottom-up approach passage of the needles and sling. Adjustment of sling tension. Closure of vaginal and skin incisions.
Study: NCT02672735

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corrective Exercise Programming
Description: Participants will be given a four-week corrective exercise protocol, with four corrective exercise sessions prescribed each week. Participants in the CEP Group will be required to complete a minimum of three of these four training sessions per week throughout the four-week corrective exercise program intervention. All corrective exercise programming will be created through the Fusionetics Human Performance System. This system, along with weekly compliance questionnaires, will also assess the compliance-level among the participants.
Study: NCT01061749

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selumetinib
Description: Given PO
Study: NCT04701775

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Only Lactobacillus rhamnosus GG strains
Description: 1x106 colony forming unit (CFU) Lactobacillus rhamnosus GG probiotic capsule

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Combined Lactobacillus acidophilus and Bifidobacterium animalis subsp.lactis strains
Description: combination of Lactobacillus acidophilus 1x109 CFU and Bifidobacterium animalis subsp.lactis 1x109 CFU probiotic capsule

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo probiotic capsule
Study: NCT00458484

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Series I: Radiation will be delivered in 4 fractions.~Series II: Radiation will be delivered in 3 fractions.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: stereotactic radiosurgery
Description: Series I: Radiation will be delivered in 4 fractions.~Series II: Radiation will be delivered in 3 fractions.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Biopsy
Description: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Renal Biopsy
Description: At 6 months,an optional percutaneous renal biopsy will be obtained of the targeted tumor, under ultrasound (US) or CT guidance.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serum Blood Markers
Description: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
Study: NCT01615822

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OZ439 400mg
Description: OZ439 400mg oral suspension, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MQ 250 mg, single dose
Description: Mefloquine 250 mg tablet, single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MQ 750mg, single dose
Description: Mefloquine 750mg oral tablet, single dose
Study: NCT00458484

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Serum Blood Markers
Description: ELISA blood testing just prior to and immediately following each daily radiation therapy session. Approximately 5cc of blood will be collected within 2 hours prior to and following completion of fractionated radiation therapy to assess the levels of MIF (both MIF-1 and MIF-2) and VEGF.
Study: NCT03697811

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DE-117 Ophthalmic Solution
Description: Interventional treatment will be made with DE-117 Ophthalmic Solution 0.002% once daily in the evening for the duration of the 3 month treatment period.
Study: NCT01440946

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rFIXFc
Description: Vials of rFIXFc were combined as needed, based on the actual labeled potency to achieve the participant's calculated dose. Partial vial use was allowed, in order to achieve the calculated dose.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FIX
Description: Vials of prestudy FIX (provided by the participants) were combined as needed, based on the nominal labeled potency (e.g., 250 IU, 500 IU, and 1000 IU), to achieve the participant's calculated dose.
Study: NCT04860310

Intervention type: PROCEDURE
Intervention: Endometrial biopsy
Description: Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.

Intervention type: PROCEDURE
Intervention: Endometrial biopsy
Description: Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.

Intervention type: PROCEDURE
Intervention: Endometrial biopsy
Description: Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.

Intervention type: PROCEDURE
Intervention: Endometrial biopsy
Description: Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.

Intervention type: PROCEDURE
Intervention: Endometrial biopsy
Description: Subjects need to collect 5ml whole blood (EDTA or heparin anticoagulant) once in the morning on an empty stomach. Endometrial tissue samples were taken during a complete 28-day menstrual cycle, a total of 6 times, and blood was taken to measure the level of gonadal hormones before each sampling.
Study: NCT02577965

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous Coronary Intervention
Description: Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Percutaneous Coronary Intervention
Description: Thrombus aspiration and histopathological analysis ,Optical Coherence Tomography assessment of culprit vessel during primary PCI, Primary PCI and Drug Eluting Stent (DES) - XIENCE PRIME Everolimus Eluting Coronary Stent implantation in culprit lesion, coronary angiography and OCT assessment at 9 months follow-up

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: XIENCE PRIME Everolimus Eluting Coronary Stent System
Description: Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
Study: NCT01615822

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT03759509

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: the experimental group, in which aerobic exercise training is given three times a week, a total of twenty-four times in eight weeks
Study: NCT03813160

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenabasum 20 mg
Description: oral capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenabasum 5 mg
Description: oral capsule

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: oral capsule
Study: NCT02577965

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: XIENCE PRIME Everolimus Eluting Coronary Stent System
Description: Xience Prime Everolimus Eluting Coronary Stent System implantation to treat Acute Myocardial Infarction
Study: NCT01652456

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Addiction support
Description: one consultation with an addiction specialist
Study: NCT02616003

Intervention type: DRUG
Group type: OTHER
Intervention: Liraglutide
Description: Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)

Intervention type: OTHER
Group type: OTHER
Intervention: Aminosteril hepa 8%
Description: Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 800 kcal from day 1 onwards till technical operability is achieved (about 21 days)

Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Caloric diet with 1000 kcal
Description: Initially 1.2 mg Liraglutide as subcutaneous daily injection, boosted to 1.8 mg Liraglutide after 3 days subsequently. 1000 ml infusion of aminosteril hepa 8% from day 1 onwards. Caloric diet with 1000 kcal from day 1 onwards till technical operability is achieved (about 21 days)
Study: NCT02338752

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: MV
Description: MV is an intravenous intralipid suspension with 5 various vaccines, including DPT (diphtheria, pertussis, and tetanus ), typhoid, Staphylococcus aureus, paratyphoid A and B. Accessories include microbial A, lecithin, Twain-80, span 20 and soy-bean oil for injection. Inject 0.5 ml of the mixture subcutaneously every week. Best reaction after injection was defined as showing regional red and swollen at the injection point and mild fever and to achieve this, dose increasing or reduction is acceptable.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment
Description: Patient will receive a comprehensive histological and imaging check up to evaluate the histological type, stage of the disease and performance status. Then the patient will receive standard treatment, in brief, surgical resection for early stage patients and systemic treatment including chemotherapy for advanced stage patients, according to NCCN guide line.
Study: NCT00289848

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin phosphate
Description: Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Comparator: placebo
Description: placebo to match Sitagliptin 100 mg administered as one oral tablet once daily before the morning meal for up to 18 weeks
Study: NCT04066452

Intervention type: DIAGNOSTIC_TEST
Intervention: Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP).
Description: Bone-cardiac scintigraphy with Tc-DPD (or similar: Tc-PYP or Tc-HMDP) to evaluate the degree of cardiac uptake from 0 to 3 degrees.
Study: NCT01930058

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8876
Description: MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8876
Description: MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MK-8876
Description: MK-8876 10 mg or 100 mg tablets taken q.d. by mouth.
Study: NCT03938142

Intervention type: OTHER
Intervention: Filling in an online survey regarding goalsettings
Description: Patients are asked to fill in an online survey regarding their individual goalsettings.
Study: NCT01603875

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).
Description: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).
Description: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: New Chromatographically Purified Vero-cell Rabies vaccine(new CPRV).
Description: new CPRV 0.1 ml intradermal route and 0.5 ml intramuscular route are the experimental intervention
Study: NCT04596540

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212 low-dose
Description: SEL-212 low-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.1 mg/kg) Other Names: SEL-110, ImmTOR

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SEL-212 high-dose
Description: SEL-212 high-dose Drug: SEL-037 (0.2 mg/kg) SEL-037, PEGylated uric acid specific enzyme (uricase) Other Names: Pegadricase, pegsiticase~Drug: SEL-110.36 (0.15 mg/kg) Other Names: SEL-110, ImmTOR

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Normal saline
Study: NCT00499135

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluorothymidine F-18
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib Malate
Description: Given PO
Study: NCT03580096

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Core stability
Description: Core stability intervention will be done with different stages and increasing gradually. The training program starts with exercises that isolate specific core muscles but progressing to include complex movements and incorporate core stability in dynamic tasks.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard intervention
Description: Standard intervention will include active exercises based on active joint mobilizations, muscle stretching and motor coordination.